Experimental gene therapy offers hope for rare heart disease

NCT ID NCT06092034

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 23 times

Summary

This study tests a gene therapy called RP-A501 in 14 males aged 8 and older with Danon disease, a rare genetic condition that weakens the heart. The therapy uses a harmless virus to deliver a working copy of the LAMP2 gene, aiming to improve heart muscle function and reduce thickening. Participants will be monitored for safety and heart changes over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DANON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Email: •••••@•••••

  • German Heart Center Munich

    RECRUITING

    Munich, Germany

    Contact Email: •••••@•••••

  • Great Ormund Street Hospital & UCL Institute of Cardiovascular Science

    RECRUITING

    London, United Kingdom

    Contact Email: •••••@•••••

  • Meyer Childrens Hospital

    RECRUITING

    Florence, Italy

    Contact Email: •••••@•••••

  • University of California, San Diego

    RECRUITING

    La Jolla, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.